LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Equities Close Higher Ahead of This Week's Major Earnings MT
Equities Close Higher Ahead of Major Earnings MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
US Equities End Higher Monday as Markets Await Corporate Earnings MT
Stifel Adjusts IQVIA Holdings' Price Target to $312 From $288 MT
Equity Markets Rise Intraday as Investors Await This Week's Major Earnings MT
Sector Update: Health Care Stocks Higher Monday Afternoon MT
US Equity Indexes Climb as Mega-cap Technology, Communication Services Heavyweights Advance in Midday Trading MT
Sector Update: Health Care MT
IQVIA Holdings Shares Rise After Reporting Higher Adjusted Earnings, Revenue, 2024 EPS Outlook MT
US Equity Indexes Rise in Midday Trading as Technology Sector Rebounds MT
Sector Update: Health Care Stocks Rise in Monday's Premarket Hours MT
Transcript : IQVIA Holdings Inc., Q2 2024 Earnings Call, Jul 22, 2024
Sector Update: Health Care MT
IQVIA raises annual profit forecast on improving demand for analytics services RE
IQVIA Holdings Q2 Adjusted Earnings, Revenue Climb; 2024 Guidance Updated MT
Stocks Gain Pre-Bell as Biden Drops Presidential Bid; Asia Down, Europe Rises MT
Earnings Flash (IQV) IQVIA HOLDINGS Reports Q2 Revenue $3.81B, vs. Street Est of $3.79B MT
Earnings Flash (IQV) IQVIA HOLDINGS Reports Q2 EPS $2.64, vs. Street Est of $2.56 MT
IQVIA Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
IQVIA Holdings Inc. Updates Earnings Guidance for the Full Year 2024 CI
ANI Pharmaceuticals Launches L-Glutamine Oral Powder Following FDA Approval MT
Leerink Partners Adjusts Price Target on IQVIA to $267 From $278, Maintains Outperform Rating MT
Baird Adjusts Price Target on IQVIA to $235 From $241 MT
Evercore ISI Adjusts Price Target on IQVIA Holdings to $230 From $250, Maintains Outperform Rating MT
Chart Iqvia Holdings Inc.
More charts
Logo Iqvia Holdings Inc.
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).
Employees
87,000
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
245.23USD
Average target price
275.25USD
Spread / Average Target
+12.24%
Consensus
  1. Stock Market
  2. Equities
  3. IQV Stock
  4. News Iqvia Holdings Inc.
  5. Truist Adjusts IQVIA Holdings' Price Target to $292 From $297, Keeps Buy Rating